Lisata Therapeutics
LSTA
20 hedge funds and large institutions have $2.3M invested in Lisata Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.16% more ownership
Funds ownership: 9.05% → 9.21% (+0.16%)
9% less funds holding
Funds holding: 22 → 20 (-2)
12% less capital invested
Capital invested by funds: $2.61M → $2.3M (-$314K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.41K |
| 4 |
Renaissance Technologies
New York
|
+$6.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$11.3K |
| 2 |
Citigroup
New York
|
-$4.98K |
| 3 |
CP
Castleview Partners
Dallas,
Texas
|
-$3.47K |
| 4 |
Morgan Stanley
New York
|
-$3.42K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
-$21 |
LSTA Hedge Fund Activity: Q3 2024 in Review
20 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2024, worth a combined $2.3M — down 12% from $2.61M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LSTA and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.7K. The largest seller was UBS Group, cutting an estimated $11.3K.
- 20 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2024, down from 22 in Q2 2024.
- Funds reported $2.3M of Lisata Therapeutics stock for Q3 2024, down 12% quarter-over-quarter.
- 1 fund opened new Lisata Therapeutics positions in Q3 2024 and 3 closed out, a net change of -2 holders.
- The largest Lisata Therapeutics buyer in Q3 2024 was Susquehanna International Group, an estimated $34.7K added.
- The largest Lisata Therapeutics seller in Q3 2024 was UBS Group, an estimated $11.3K sold.
Based on aggregated 13F filings for Q3 2024.